FRIL, which is overexpressed in high grade glioma, mainly associated with IDH1/2 wildtype and unfavorable prognosis of these glioma patients [113], has also been indicated as a biomarker together with ferritin heavy chain to predict prognosis and temozolomide resistance in glioma patients [114]. Here, IDH1 is linked to central nervous system cancer.